Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CANCER CARE
Volume 26, Issue 5, Pages e12407
Publisher
Wiley
Online
2015-11-05
DOI
10.1111/ecc.12407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).
- (2017) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Task Force Report: Management of Neuropathy in Cancer
- (2017) Michael D. Stubblefield et al. Journal of the National Comprehensive Cancer Network
- Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
- (2014) Yasutsuna Sasaki et al. CANCER SCIENCE
- SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
- (2014) Neil Desai et al. Translational Oncology
- Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
- (2013) Yoo-Joung Ko et al. LANCET ONCOLOGY
- A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
- (2012) Peter J. Hosein et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
- (2012) David S. Alberts et al. GYNECOLOGIC ONCOLOGY
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
- (2011) Paul K. Paik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis
- (2011) Ta-Chen Huang et al. CANCER TREATMENT REVIEWS
- A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer
- (2011) Barry Mirtsching et al. Clinical Breast Cancer
- Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence
- (2011) David Balayssac et al. Expert Opinion On Drug Safety
- A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study
- (2011) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
- (2010) Christopher Lobo et al. BREAST CANCER RESEARCH AND TREATMENT
- Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies
- (2010) Gerardo Gutiérrez-Gutiérrez et al. Clinical & Translational Oncology
- Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
- (2010) Alison K. Conlin et al. Clinical Breast Cancer
- Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
- (2010) Javier Cortes et al. EJC SUPPLEMENTS
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
- (2010) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis
- (2009) Davide Mauri et al. CANCER TREATMENT REVIEWS
- Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- (2009) Michael G. Teneriello et al. JOURNAL OF CLINICAL ONCOLOGY
- Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
- (2009) William J. Gradishar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
- (2009) D.R. Shepard et al. JOURNAL OF UROLOGY
- Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer
- (2008) Edgardo Rivera et al. CANCER
- Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer
- (2008) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-induced neuropathy
- (2008) Anthony J. Windebank et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started